Send the following on WhatsApp
Continue to Chat嬌生首個細胞療法 Carvykti,核准用於治療復發與難治性多發性骨髓瘤 https://geneonline.news/janssen-approval-carvykti-rrmm/?variant=zh-cn
嬌生首個細胞療法 Carvykti,核准用於治療復發與難治性多發性骨髓瘤 https://geneonline.news/janssen-approval-carvykti-rrmm/?variant=zh-cn